Algeta ASA : Primary Insider Transaction in the Repair Offering
NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR
Ikke for distribusjon i USA, Canada, Japan eller Australia.
Oslo, 8 March 2012
Algeta ASA (Ticker: ALGETA) (the "Company") announces primary insider
transaction in connection with the repair offering (the "Repair Offering").
In connection with the ongoing subscription period for the Repair Offering in
the Company, Øystein Soug, Chief Financial Officer of Algeta, has today
subscribed for 700 shares in the Company at a subscription price of NOK 143 per
share. After the completion of the Repair Offering, Øystein Soug will hold
17,200 shares and 105,628 options for shares in the Company.
For further information, please contact
Mike Booth +47 2202 4510
Communications & Corporate Affairs
International media enquiries: +44 207 638 9571
Citigate Dewe Rogerson
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is in development as a
potential new treatment for cancer patients with bone metastases. It is in pre-
registration for castration-resistant prostate cancer (CRPC) patients with bone
metastases, and filings are expected mid 2012 in the USA and Europe; Alpharadin
has Fast Track designation for this indication in the USA.
Alpharadin is also under clinical investigation in breast cancer patients with
bone metastases and in combination with docetaxel chemotherapy in CPRC patients
with bone metastases.
Alpharadin is being developed and will be commercialized, pending approval,
under a global agreement with Bayer Pharma AG.
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
This publication constitutes neither an offer to sell nor an invitation to buy
securities. The offer in Norway will be made exclusively by means of and on the
basis of the approved prospectus which is published on the website of Algeta ASA
and available free of charge at Algeta ASA and manager.
Any offer of securities to the public that may be deemed to be made pursuant to
this publication in any EEA Member State that has implemented Directive
2003/71/EC (together with any applicable implementing measures in any EEA Member
State, the "Prospectus Directive") is only addressed to and is only directed at
qualified investors in that EEA Member State within the meaning of the
Dette materialet representerer ikke et tilbud om salg eller kjøp av
verdipapirer. Tilbudet i Norge vil kun bli fremsatt i henhold til og på bakgrunn
av det godkjente prospektet som er publisert på hjemmesiden til Algeta ASA og
som kan fås vederlagsfritt ved henvendelse til Algeta ASA og tilrettelegger.
Ethvert tilbud om salg av verdipapirer til det offentlige som kan bli gitt i
henhold til dette dokumentet i enhver EØS-stat som har implementert Direktiv
2003/71/EU (sammen med ethvert gjeldende implementeringstiltak i enhver EØS-
stat, "Prospekt Direktivet") er kun adressert til og kun ment for profesjonelle
investorer i henhold til Prospekt Direktivet i den EØS-staten.
These materials are not and do not form part of an offer of or solicitation to
purchase or subscribe securities in the United States. The securities to which
these materials relate have not been registered under the U.S. Securities Act of
1933 (the "Securities Act") or
under the securities legislation of any state of the United States, and may not
be offered or sold in the United States absent registration under or pursuant to
an exemption from, or in a transaction not subject to, the registration
requirements under the Securities Act. There will be no public offering of the
securities in the United States.
This document is only being distributed to and is only directed at (i) persons
who are outside the United Kingdom or (ii) to investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other
persons to whom it may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being referred to as
"relevant persons"). The securities are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, relevant persons. Any person who is not a relevant
person should not act or rely on this document or any of its contents.
This news release contains certain forward-looking statements based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. Such forward-looking
statements reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance to the correctness of such
statements. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements. These factors include, among other things, risks or
uncertainties associated with the success of future clinical trials,
collaborations with other companies in the development of targeting molecules
and alpha particle payloads, risks associated with technological development,
growth management, general economic and business conditions and the pricing
environment, the impact of competition, the ability to successfully
commercialize Alpharadin and our other products, the risk that research &
development will not yield new products that achieve commercial success,
manufacturing capacity, the risk of non-approval of patents not yet granted,
risks in obtaining regulatory approvals for Alpharadin and our other products
and difficulties of obtaining relevant governmental approvals for new products,
and the other risks and uncertainties described in our annual report.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.